Depression bei Morbus Parkinson: Epidemiologie und Therapie

Lernziele

1. Häufigkeiten und Auftretenswahrscheinlichkeiten depressiver Erkrankungen bei Patienten mit der Parkinson-Krankheit einschätzen zu können.

2. Bisherige Ergebnisse zur Häufigkeit anhand der verwendeten Studienmethodik einordnen zu können.

3. Zusammenhänge zwischen depressiven Störungen und soziodemografischen und klinischen Variablen zu erfahren.

4. Überblick über den aktuellen Stand zur medikamentösen Behandlung depressiver Störungen bei Patienten mit der Parkinson-Krankheit zu gewinnen.

5. Informationen über weitere Behandlungsansätze zu erhalten.

• Literatur

• 1 Parkinson J. An Essay on the Shaking Palsy. London: Sherwood, Neely and Jones; 1817
• 2 Schrag A, Jahanshahi M, Quinn N. How does Parkinson’s disease affect quality of life? A comparison with quality of life in the general population. Movement Disord 2000; 15: 1112-1118
• 3 Bach J-P, Riedel O, Klotsche J et al. Impact of complications and comorbidities on treatment costs and health-related quality of life in patients with Parkinson’s disease. J Neurol Sci 2012; 314: 41-47
• 4 Winter Y, Balzer-Geldsetzer M, Spottke A et al. Longitudinal study of the socioeconomic burden of Parkinson’s disease in Germany. Eur J Neurol 2010; 17: 1156-1163
• 5 Gallagher DA, Schrag A. Psychosis, apathy, depression and anxiety in Parkinson’s disease. Neurobiol Dis 2012; 46: 581-589
• 6 Reijnders J, Ehrt U, Weber WEJ et al. A systematic review of prevalence studies of depression in Parkinson’s disease. Movement Disord 2008; 23: 183-189
• 7 Leentjens AFG. Depression in Parkinson’s disease: conceptual issues and clinical challenges. J Geriatr Psychiat Neurol 2004; 17: 120-126
• 8 Farabaugh AH, Locascio JJ, Yap L et al. Assessing depression and factors possibly associated with depression during the course of Parkinson’s disease. Ann Clin Psychiatry 2011; 23: 171-177
• 9 Hu M, Cooper J, Beamish R et al. How well do we recognise non-motor symptoms in a British Parkinson’s disease population?. J Neurol 2011; 258: 1513-1517
• 10 Marsh L, McDonald WM, Cummings J et al. Provisional diagnostic criteria for depression in Parkinson’s disease: Report of an NINDS/NIMH work group. Movement Disord 2006; 21: 148-158
• 11 Zheng J, Sun SG, Qiao X et al. Depression in patients with Parkinson’s disease and the associated features. J Huazhong Univ Sci Tech-Med 2009; 29: 725-728
• 12 Joutsa J, Martikainen K, Vahlberg T et al. Impulse control disorders and depression in Finnish patients with Parkinson’s disease. Parkinsonism Relat Disord 2012; 18: 155-160
• 13 Piccinni A, Marazziti D, Veltri A et al. Depressive symptoms in Parkinson’s disease. Compr Psychiat 2012; 53: 727-731
• 14 Bugalho P, da Silva JA, Cargaleiro I et al. Psychiatric symptoms screening in the early stages of Parkinson’s disease. J Neurol 2012; 259: 124-131
• 15 Coelho M, Marti MJ, Tolosa E et al. Late-stage Parkinson’s disease: the Barcelona and Lisbon cohort. J Neurol 2010; 257: 1524-1532
• 16 Riedel O, Heuser I, Klotsche J et al. Occurrence risk and structure of depression in Parkinson disease with and without dementia: results from the GEPAD study. J Geriatr Psychiat Neurol 2010; 23: 27-34
• 17 Cummings JL, Masterman DL. Depression in patients with Parkinson’s disease. Int J Geriatr Psychiatr 1999; 14: 711-718
• 18 Spica V, Pekmezovic T, Svetel M et al. Prevalence of non-motor symptoms in young-onset versus late-onset Parkinson’s disease. J Neurol 2013; 260: 131-137
• 19 Anguenot A, Loll PY, Neau JP et al. Depression and Parkinson’s disease: a study of 135 parkinsonian patients. Can J Neurol Sci 2002; 29: 139-146
• 20 Burn DJ, Landau S, Hindle JV et al. Parkinson’s disease motor subtypes and mood. Movement Disord 2012; 27: 379-386
• 21 Schrag A, Jahanshahi M, Quinn NP. What contributes to depression in Parkinson’s disease?. Psychol Med 2001; 31: 65-73
• 22 Starkstein SE, Petracca G, Chemerinski E et al. Depression in classic versus akinetic-rigid Parkinson’s disease. Movement Disord 1998; 13: 29-33
• 23 Holroyd S, Currie LJ, Wooten GF. Depression is associated with impairment of ADL, not motor function in Parkinson disease. Neurology 2005; 64: 2134-2135
• 24 Kessler RC, Petukhova M, Sampson NA et al. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res 2012; 21: 169-184
• 25 Solla P, Cannas A, Ibba FC et al. Gender differences in motor and non-motor symptoms among Sardinian patients with Parkinson’s disease. J Neurol Sci 2012; 323: 33-39
• 26 Jacob EL, Gatto NM, Thompson A et al. Occurrence of depression and anxiety prior to Parkinson’s disease. Parkinsonism Relat Disord 2010; 16: 576-581
• 27 Poletti M, De Rosa A, Bonuccelli U. Affective symptoms and cognitive functions in Parkinson’s disease. J Neurol Sci 2012; 317: 97-102
• 28 Riedel O, Klotsche J, Spottke A et al. Cognitive impairment in 873 patients with idiopathic Parkinson’s disease: results from the German Study on Epidemiology of Parkinson’s Disease with Dementia (GEPAD). J Neurol 2008; 255: 255-264
• 29 Starkstein S, Dragovic M, Jorge R et al. Diagnostic criteria for depression in Parkinson’s disease: a study of symptom patterns using latent class analysis. Movement Disord 2011; 26: 2239-2245
• 30 Morgante L, Colosimo C, Antonini A et al. Psychosis associated to Parkinson’s disease in the early stages: relevance of cognitive decline and depression. J Neurol Neurosurg Psychiatry 2012; 83: 76-82
• 31 Ziropadja L, Stefanova E, Petrovic M et al. Apathy and depression in Parkinson’s disease: the Belgrade PD study report. Parkinsonism Relat Disord 2012; 18: 339-342
• 32 Aarsland D, Pahlhagen S, Ballard CG et al. Depression in Parkinson disease – epidemiology, mechanisms and management. Nat Rev Neurol 2012; 8: 35-47
• 33 Dooneief G, Mirabello E, Bell K et al. An estimate of the incidence of depression in idiopathic Parkinson’s disease. Arch Neurol 1992; 49: 305-307
• 34 Dissanayaka NNW, Sellbach A, Silburn PA et al. Factors associated with depression in Parkinson’s disease. J Affect Disord 2011; 132: 82-88
• 35 Kulkantrakorn K, Jirapramukpitak T. A prospective study in one year cumulative incidence of depression after ischemic stroke and Parkinson’s disease: a preliminary study. J Neurol Sci 2007; 263: 165-168
• 36 Leentjens A, van den Akker M, Metsemakers J et al. Higher incidence of depression preceding the onset of Parkinson’s disease: a register study. Movement Disord 2003; 18: 414-418
• 37 Nilsson FM, Kessing LV, Bolwig TG. Increased risk of developing Parkinson’s disease for patients with major affective disorder: a register study. Acta Psychiatr Scand 2001; 104: 380-386
• 38 Skeie GO, Muller B, Haugarvoll K et al. Parkinson disease: associated disorders in the Norwegian population based incident ParkWest study. Parkinsonism Relat Disord 2013; 19: 53-55
• 39 Meara J, Mitchelmore E, Hobson P. Use of the GDS-15 geriatric depression scale as a screening instrument for depressive symptomatology in patients with Parkinson’s disease and their carers in the community. Age and Ageing 1999; 28: 35-38
• 40 Osborn DPJ, Fletcher A, Smeeth L et al. Geriatric depression scale scores in a representative sample of 14545 people aged 75 and over in the United Kingdom: results from the MRC Trial of Assessment and Management of Older People in the Community. Int J Geriatr Psychiatr 2002; 17: 375-382
• 41 Leentjens A, Verhey F, Lousberg R et al. The validity of the Hamilton and Montgomery-Asberg depression rating scales as screening and diagnostic tools for depression in Parkinson’s disease. Int J Geriatr Psychiatr 2000; 15: 644-649
• 42 Schrag A, Barone P, Brown R et al. Depression rating scales in Parkinson’s disease: critique and recommendations. Movement Disord 2007; 22: 1077-1092
• 43 DGPPN, BÄK, KBV et al. eds. S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare Depression – Kurzfassung. Berlin, Düsseldorf: 2009
• 44 Seppi K, Weintraub D, Coelho M et al. The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the non-motor symptoms of Parkinson’s disease. Movement Disord 2011; 26: S42-S80
• 45 Chaudhuri KR, Martinez-Martin P, Antonini A et al. Rotogotine and specific non-motor symptoms of Parkinson’s disease: post-hoc analysis of RECOVER. Parkinsonism Relat Disord 2013; 19: 660-665
• 46 Franco-Chaves J, Mateus C, Luckenbaugh D et al. Combining a dopamine agonist and selective serotonin reuptake inhibitor for the treatment of depression: a double-blind, randomized pilot study. J Affect Disord 2013; 149: 319-325
• 47 Korchounov A, Winter Y, Rossy W. Combined beneficial effect of rasagiline on motor function and depression in de novo PD. Clin Neuropharmacol 2012; 35: 121-124
• 48 Richard IH, McDermott MP, Kurlan R et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 2012; 78: 1229-1236
• 49 Bertaina-Anglade V, La Rochelle CD, Scheller DKA. Antidepressant properties of rotigotine in experimental models of depression. Eur J Pharmacol 2006; 548: 106-114
• 50 Bauer M, Whybrow PC, Angst J et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for biological treatment of unipolar depressive disorders, part 2: maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. Rev Psiquiatr Clin 2009; 36: 58-76
• 51 Devos D, Dujardin K, Poirot I et al. Comparison of desipramine and citalopram treatments for depression in Parkinson’s disease: a double-blind, randomized, placebo-controlled study. Movement Disord 2008; 23: 850-857
• 52 Wermuth L, Sorensen PS, Timm S et al. Depression in idiopathic Parkinson’s disease treated with citalopram. A placebo-controlled trial. Nord J Psychiatr 1998; 52: 163-169
• 53 Avila A, Cardona X, Martin-Baranera M et al. Does nefazodone improve both depression and Parkinson disease? A pilot randomized trial. J Clin Psychopharmacol 2003; 23: 509-513
• 54 Fregni F, Santos CM, Myczkowski ML et al. Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 2004; 75: 1171-1174
• 55 Leentjens AFG, Vreeling FW, Luijckx GJ et al. SSRIs in the treatment of depression in Parkinson’s disease. Int J Geriatr Psychiatr 2003; 18: 552-554
• 56 Antonini A, Tesei S, Zecchinelli A et al. Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson’s disease and depression: effect on quality of life. Movement Disord 2006; 21: 1119-1122
• 57 Barone P, Scarzella L, Marconi R et al. Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease – a national multicenter parallel-group randomized study. J Neurol 2006; 253: 601-607
• 58 Weintraub D, Mavandadi S, Mamikonyan E et al. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology 2010; 75: 448-455
• 59 Therapies for depression in Parkinson’s disease. Cochrane Database Syst Rev 2003;
• 60 Takahashi H, Kamata M, Yoshida K et al. Remarkable effect of milnacipran, a serotonin-noradrenalin reuptake inhibitor (SNRI), on depressive symptoms in patients with Parkinson’s disease who have insufficient response to selective serotonin reuptake inhibitors (SSRIs): two case reports. Prog Neuro-Psychopharmacol Biol Psychiatry 2005; 29: 351-353
• 61 Lemke MR. Effect of reboxetine on depression in Parkinson’s disease patients. J Clin Psychiatry 2002; 63: 300-304
• 62 Leentjens AFG, Verhey FRJ, Vreeling FW. Successful treatment of depression in Parkinson’s disease patient with bupropion. Ned Tijdschr Geeeskd 2000; 144: 2157-2159
• 63 Stoppe G. Depressionen im Alter. Bundesgesundheitsblatt 2008; 51: 406-410
• 64 Ehrt U, Bronnick K, Leentjens AFG et al. Depressive symptom profile in Parkinson’s disease: a comparison with depression in elderly patients without Parkinson’s disease. Int J Geriatr Psychiatr 2006; 21: 252-258
• 65 Gotham AM, Brown RG, Marsden CD. Depression in Parkinson’s disease – a quantitative and qualitative analysis. J Neurol Neurosurg Psychiatry 1986; 49: 381-389
• 66 Merschdorf U, Berg D, Csoti I et al. Psychopathological symptoms of depression in Parkinson’s disease compared to major depression. Psychopathol 2003; 36: 221-225
• 67 Kummer A, Cardoso F, Teixeira AL. Suicidal ideation in Parkinson’s disease. CNS Spectr 2009; 14: 431-436
• 68 Funkiewiez A, Ardouin C, Caputo E et al. Long-term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2004; 75: 834-839
• 69 Soulas T, Gurruchaga JM, Palfi S et al. Attempted and completed suicides after subthalamic nucleus stimulation for Parkinson’s disease. J Neurol Neurosurg Psychiatry 2008; 79: 952-954
• 70 Strutt AM, Simpson R, Jankovic J et al. Changes in cognitive-emotional and physiological symptoms of depression following STN-DBS for the treatment of Parkinson’s disease. Eur J Neurol 2012; 19: 121-127
• 71 Voon V, Krack P, Lang AE et al. A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson’s disease. Brain 2008; 131: 2720-2728
• 72 Toft M, Lilleeng B, Ramm-Pettersen J et al. Long-Term efficacy and mortality in Parkinson’s disease patients treated with subthalamic stimulation. Movement Disord 2011; 26: 1931-1934
• 73 Cole K, Vaughan FL. The feasibility of using cognitive behaviour therapy for depression associated with Parkinson’s disease: a literature review. Parkinsonism Relat Disord 2005; 11: 269-276
• 74 Dobkin RD, Menza M, Allen LA et al. Cognitive-behavioral therapy for depression in Parkinson’s disease: a randomized, controlled trial. Am J Psychiat 2011; 168: 1066-1074
• 75 Dobkin RD, Allen LA, Menza M. Cognitive-behavioral therapy for depression in Parkinson’s disease: a pilot study. Movement Disord 2007; 22: 946-952
• 76 Farabaugh A, Locascio JJ, Yap L et al. Cognitive-behavioral therapy for patients with Parkinson’s disease and comorbid major depressive disorder. Psychosomatics 2010; 51: 124-129
• 77 Dobkin RD, Menza M, Allen LA et al. Telephone-based cognitive-behavioral therapy for depression in Parkinson disease. J Geriatri Psychiatr Neurol 2011; 24: 206-214
• 78 Brand S, Dodel R, Hautzinger M et al. Depression in Parkinson’s disease. Assessment and treatment. Nervenarzt 2007; 78: 715-727
• 79 Dobkin RD, Rubino JT, Allen LA et al. Predictors of treatment response to cognitive-behavioral therapy for depression in Parkinson’s disease. J Consult Clin Psychol 2012; 80: 694-699
• 80 Sproesser E, Viana MA, Quagliato E et al. The effect of psychotherapy in patients with PD: a controlled study. Parkinsonism Relat Disord 2010; 16: 298-300
• 81 A’Campo LEI, Wekking EM, Spliethoff-Kamminga NGA et al. The benefits of a standardized patient education program for patients with Parkinson’s disease and their caregivers. Parkinsonism Relat Disord 2010; 16: 89-95
• 82 A’Campo LEI, Wekking EM, Spliethoff-Kamminga NGA et al. Treatment effect modifiers for the patient education programme for Parkinson’s disease. Int J Clin Pract 2012; 66: 77-83
• 83 Macht M, Gerlich C, Ellgring H et al. Patient education in Parkinson’s disease: formative evaluation of a standardized programme in seven European countries. Patient Educ Couns 2007; 65: 245-252
• 84 Fitzpatrick L, Simpson J, Smith A. A qualitative analysis of mindfulness-based cognitive therapy (MBCT) in Parkinson’s disease. Psychol Psychother-Theory Res Pract 2010; 83: 179-192
• 85 Strehl U, Birbaumer N. Verhaltensmedizinische Interventionen beim Morbus Parkinson. Weinheim: Beltz; 1996
• 86 Yang S, Sajatovic M, Walter BL. Psychosocial interventions for depression and anxiety in Parkinson’s disease. J Geriatr Psychiatr Neurol 2012; 25: 113-121
• 87 Hemmeter U, Hemmeter-Spernal J, Krieg J. Sleep deprivation in depression. Expert Rev Neurother 2010; 10: 1101-1115
• 88 Demet EM, Chicz-Demet A, Fallon JH et al. Sleep deprivation therapy in depressive illness and Parkinson’s disease. Prog Neuro-Psychopharmacol Biol Psychiatry 1999; 23: 753-784
• 89 Willis GL, Moore C, Armstrong SM. A historical justification for and retrospective analysis of the systematic application of light therapy in Parkinson’s disease. Rev Neurosci 2012; 23: 199-226
• 90 Paus S, Schmitz-Hubsch T, Wullner U et al. Bright light therapy in Parkinson’s disease: a pilot study. Mov Disord 2007; 22: 1495-1498
• 91 Fregni F, Simon DK, Wu A et al. Non-invasive brain stimulation for Parkinson’s disease: a systematic review and meta-analysis of the literature. J Neurol Neurosurg Psychiatr 2005; 76: 1614-1623
• 92 Pal E, Nagy F, Aschermann Z et al. The impact of left prefrontal repetitive transcranial magnetic stimulation on depression in Parkinson’s disease: a randomized, double-blind, placebo-controlled study. Movement Disord 2010; 25: 2311-2317
• 93 Arun MP, Bharath S, Pal PK et al. Relationship of depression, disability, and quality of life in Parkinson’s disease: a hospital-based case-control study. Neurol India 2011; 59: 185-189
• 94 Barone P, Antonini A, Colosimo C et al. The Priamo Study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Movement Disord 2009; 24: 1641-1649
• 95 Braam AW, Beekman ATF, Dewey ME et al. Depression and parkinsonism in older Europeans: results from the EURODEP concerted action. Int J Geriatr Psychiatr 2010; 25: 679-687
• 96 Khedr EM, El Fetoh NA, Khalifa H et al. Prevalence of depression, anxiety, dementia and other non motor features of a large cohort of Egyptian Parkinson’s disease patients. Life Sci J 2012; 9: 509-518
• 97 Oguru M, Tachibana H, Toda K et al. Apathy and depression in Parkinson disease. J Geriatr Psychiatr Neurol 2010; 23: 35-41
• 98 Rodriguez-Violante M, Cervantes-Arriaga A, Berlanga-Flores C et al. Prevalence and determinants of depression in Mexican patients with Parkinson’s disease. Clin Neurol Neurosurg 2012; 114: 1293-1296
• 99 Vanderheyden JE, Gonce M, Bourgeois P et al. Epidemiology of major depression in Belgian parkinsonian patients. Acta Neurol Belg 2010; 110: 148-156